Key result
In children with Kawasaki disease, baseline ACE levels were significantly lower (1.8 vs 7.0 pm/ml/min) and vWF levels higher (210.3% vs 99%) than controls, normalizing after i.v.IG treatment.
Why the study?
Does intravenous gamma-globulin treatment improve circulating ACE and vWF levels in children with Kawasaki disease?
Observational (n=32)
Does intravenous gamma-globulin treatment improve circulating ACE and vWF levels in children with Kawasaki disease?
ACE and vWF circulating levels are significantly modified during the acute phase of Kawasaki disease and normalize at different rates following i.v.IG treatment, suggesting potential utility as surrogate markers for endothelial derangement.
No takes yet. Share an insight, caveat, or question.
ACE and vWF may mark endothelial dysfunction in acute Kawasaki disease; hypothesis-generating for surrogate monitoring of IVIG response.
Falcini et al. (1999) conducted an observational in Kawasaki disease (n=32). Intravenous gamma-globulins (i.v.IG) vs. Healthy controls and baseline was evaluated on Circulating ACE and vWF levels. In children with Kawasaki disease, baseline ACE levels were significantly lower (1.8 vs 7.0 pm/ml/min) and vWF levels higher (210.3% vs 99%) than controls, normalizing after i.v.IG treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: